Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT02655770 Completed - Clinical trials for Diabetes Mellitus Type 2

Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients

Start date: February 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether liraglutide a GLP-1 analogue are effective in the treatment of diastolic dysfunction in type 2 diabetes patients analyzed by cardiac MRI. Secondary if the treatment has any effect on the perfusion of the heart on a cardiac-MRI.

NCT ID: NCT02650726 Completed - Clinical trials for Diabetes Mellitus,Type 2

Purified Anthocyanins Supplementation and High-Density Lipoprotein (HDL) Function

Start date: November 2014
Phase: Phase 0
Study type: Interventional

HDL function is impaired in patients with type 2 diabetes mellitus. Anthocyanin, a water-soluble compounds,is beneficial for vascular function by increasing nitric oxide (NO) bioavailability and decreasing oxidative stress. This study was designed to evaluate whether anthocyanin supplementation might improve cardiovascular function in diabetic patients.

NCT ID: NCT02650206 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Start date: January 2015
Phase: Phase 1
Study type: Interventional

The objective of this study is to test the hypothesis that liraglutide (commonly known as Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and blood, thereby reducing localized and systemic inflammation which are risk factors for cardiovascular disease and may contribute to hyperglycemia. This will be done after 4 weeks of treatment during which weight will remain stable, and again after 12 weeks, during which liraglutide-related weight loss occurs.

NCT ID: NCT02648854 Completed - Clinical trials for Diabetes Mellitus, Type II

Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers

Start date: October 2015
Phase: Phase 1
Study type: Interventional

This study is A randomized, open-label, single dose, 2-way crossover study to investigate the effect of food on the pharmacokinetic characteristics of CKD-395 in healthy male volunteers.

NCT ID: NCT02648685 Completed - Diabetes, Type 2 Clinical Trials

The Study to Investigate the Contribution of Basal and Postprandial Glucose to Overall Hyperglycemia in T2DM

Start date: November 30, 2015
Phase:
Study type: Observational

There was no any China mainland data showing the contribution of BBG and PBG to HbA1c in T2DM patients treated with OADs using the CGM method. Therefore this study is aimed to investigate the contribution of BBG and PBG to HbA1c in Chinese T2DM patients treated with OADs using CGMS. It's expected to generate evidence to support the concept of individualized therapy when patients are uncontrolled by OADs.

NCT ID: NCT02648217 Completed - Clinical trials for Diabetes Mellitus, Type 2

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Start date: January 4, 2016
Phase: Phase 3
Study type: Interventional

This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan.

NCT ID: NCT02648204 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

SUSTAIN 7
Start date: January 6, 2016
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.

NCT ID: NCT02647905 Completed - Diabetes Mellitus Clinical Trials

Evaluation of the Accuracy of an Implanted Glucose Sensor

PRECISEII
Start date: January 2016
Phase: N/A
Study type: Interventional

The purpose of this clinical investigation is to evaluate the accuracy of the Senseonics Continuous Glucose Monitoring System (Senseonics CGM System) measurements when compared with reference standard measurements The investigation will also evaluate safety of the Senseonics CGM System usage.

NCT ID: NCT02646072 Completed - Diabetes Mellitus Clinical Trials

Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients

Start date: August 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether there is a relationship between inflammatory cytokines in the aqueous of the eye and thickness of the macula after treatment of topical ketorolac for patients undergoing cataract surgery.

NCT ID: NCT02645448 Completed - Diabetes Mellitus Clinical Trials

Glycemic Responses and of the Autonomic Cardiac Function in Diabetes Type-2 Women Post Resistance Exercise

Start date: November 2014
Phase: N/A
Study type: Interventional

The aim of this study was to investigate and correlate the glucose responses and VFC 24 hours after resistance exercise (RE) sessions at different intensities in women with type 2 diabetes (DM-2). Twelve women with DM-2 were invited to perform by one week in randomized order, two weeks interventions with experimental sessions: Session Control (CONT) without conducting RE, RE session (40% or 80% of one maximum repetition - 1RM) on day 2 and day 3 was observed the effect of the length of RE session by 11h. After that, initiated the experimental sessions, where after each of the analysis of glucose 24h by continuous monitoring system of glucose was performed, considering breakfast, lunch, dinner and sleep, and analysis performed of the RR series by a period of 48h. During control sessions, the subjects were seated comfortably for 40min and RE sessions, 40%1RM and 80%1RM, were performed in medium circuit 3 sets with 16 and 8 replications and recovery range between 60 exercises and 90seg , respectively, and between the circuits 120sec. It was observed that the concentration of glucose in the period of 24h after the session has been reduced to 40% 1RM vs. CONT and 80%1RM. Hyperglycemia was prevalent in the period 34h of the sessions CONT and 80%1RM, respectively , being different from the session 40%1RM. In postprandial times, shorter hyperglycemia was found in the session to 40% 1RM vs. CONT and 80% 1RM after breakfast, lunch and dinner. At the time of sleep, less time in hyperglycemia was found between sessions of 40% 1RM vs. 80% 1RM. Significant correlations (p <0.01) were found between glucose 24h with cardiac autonomic RRi variables, HF, LF and reason LF:HF.